You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 17, 2025

CLINICAL TRIALS PROFILE FOR PHENERGAN VC


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Phenergan Vc

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00147680 ↗ Uterine Papillary Serous Cancer (UPSC) Trial Completed Queensland Centre for Gynaecological Cancer Phase 2 2004-09-01 This study will be an open, non-randomised, clinical phase 2 trial, which will involve 30 women diagnosed with uterine papillary serous cancer. The researchers will investigate the effect of four cycles of paclitaxel/carboplatin, followed by whole pelvic external beam radiotherapy to a standard pelvis field (50.4 Gy) with or without a para-aortic boost with respect to the safety and efficacy of treatment, and patterns of recurrence.
NCT00426491 ↗ Misoprostol for Non-Viable Pregnancies Completed Madigan Army Medical Center Phase 3 1999-03-01 The purpose of this study is to examine the effectiveness of Misoprostol (Cytotec; GD Searle and Co., Chicago, IL) for the management of non-viable first trimester pregnancies. Specifically, Misoprostol (15-S-15-methyl PGE1) will be compared to a placebo with expectant management in who have documented non-viable gestations. We will examine the following outcome variables: time to resolution, number of patients requiring dilation and curettage, change in hematocrit, cost to the institution, patient satisfaction, and reported side effects.
NCT00541671 ↗ Prevention of Narcotic-Induced Nausea Terminated Christiana Care Health Services N/A 2007-02-01 We are doing this study to find out if extra medicine is needed to avoid the chance of nausea sometimes linked to narcotic pain medicine (for example, morphine, dilaudid, fentanyl). Some doctors always give medicine to prevent the possible side effect of nausea, while others do not. We are looking to see if this extra medicine is helpful in preventing nausea. The goal is to screen all patients with pain and enroll enough subjects to reach our goal of 164 evaluable study participants.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Phenergan Vc

Condition Name

Condition Name for Phenergan Vc
Intervention Trials
Breast Cancer 1
Postoperative Confusion 1
Conscious Sedation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Phenergan Vc
Intervention Trials
Nausea 5
Vomiting 4
Postoperative Nausea and Vomiting 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Phenergan Vc

Trials by Country

Trials by Country for Phenergan Vc
Location Trials
United States 12
Iran, Islamic Republic of 1
Australia 1
Egypt 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Phenergan Vc
Location Trials
Florida 1
Colorado 1
Indiana 1
California 1
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Phenergan Vc

Clinical Trial Phase

Clinical Trial Phase for Phenergan Vc
Clinical Trial Phase Trials
Phase 4 5
Phase 3 2
Phase 2 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Phenergan Vc
Clinical Trial Phase Trials
Completed 7
Recruiting 3
Terminated 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Phenergan Vc

Sponsor Name

Sponsor Name for Phenergan Vc
Sponsor Trials
M.D. Anderson Cancer Center 1
University of Florida 1
EKR Therapeutics, Inc 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Phenergan Vc
Sponsor Trials
Other 21
Industry 3
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Phenergan VC: Clinical Trials, Market Analysis, and Projections

Introduction

Phenergan VC, a combination of promethazine hydrochloride and phenylephrine hydrochloride, is an oral solution used to treat upper respiratory symptoms such as cough, runny nose, and sneezing. Here, we will delve into the clinical trials, market analysis, and projections for this medication.

Clinical Trials and Safety Profile

Clinical Studies

There have been no adequate and well-controlled studies of promethazine in pregnant women, and animal reproduction studies have not been conducted with the combination of promethazine and phenylephrine[1][5].

Safety Profile

The safety profile of Phenergan VC includes several notable side effects:

  • Promethazine: Common side effects include sedation, sleepiness, blurred vision, dry mouth, and dizziness. Rare but serious side effects can include extrapyramidal symptoms, confusion, and disorientation[1].
  • Phenylephrine: Side effects can include restlessness, anxiety, nervousness, dizziness, and hypertension[1].

Overdose Information

Overdose symptoms can range from mild central nervous system depression to profound hypotension, respiratory depression, and unconsciousness. Paradoxical reactions, particularly in children, can include hyperexcitability and nightmares[1].

Market Analysis

Current Market Status

Phenergan VC, along with its variant containing codeine (Promethazine VC with Codeine), has been discontinued under the brand name in the U.S. However, generic versions may still be available and approved by the FDA[4][5].

Market Demand

The demand for upper respiratory combination medications remains steady due to the common occurrence of cold and flu symptoms. However, the market is highly competitive, with numerous other products available.

Competitive Landscape

The market for cough and cold medications is dominated by well-established brands and generic alternatives. Phenergan VC competes with other combination products that offer similar symptom relief, such as those containing antihistamines, decongestants, and sometimes codeine for cough suppression.

Projections

Future Market Trends

Given the discontinuation of the brand name and the availability of generic alternatives, the market share of Phenergan VC is expected to stabilize rather than grow significantly. However, the overall demand for upper respiratory medications is likely to remain consistent due to seasonal fluctuations and the ongoing need for symptom relief.

Regulatory Considerations

Future projections must consider regulatory changes and safety updates. For instance, the FDA's scrutiny of codeine-containing products due to concerns about opioid abuse may impact the prescribing habits for Promethazine VC with Codeine, potentially affecting the market for Phenergan VC as well[4].

Patient Preferences and Healthcare Trends

Patients are increasingly seeking medications with fewer side effects and lower risks of dependency. This trend may influence prescribing practices, with healthcare providers opting for alternative treatments that offer similar efficacy with a better safety profile.

Dosage and Administration

Recommended Dosage

The recommended dosage for Phenergan VC is as follows:

  • Adults and children 12 years and over: 1 teaspoonful (5 mL) every 4 to 6 hours, not to exceed 6 teaspoonsful (30 mL) in 24 hours.
  • Children 6 to under 12 years of age: ½ to 1 teaspoonful (2.5 to 5 mL) every 4 to 6 hours, not to exceed 6 teaspoonsful (30 mL) in 24 hours.
  • Children 2 to under 6 years of age: ¼ to ½ teaspoonful (1.25 to 2.5 mL) every 4 to 6 hours. It is not recommended for children under 2 years of age[1].

Drug Interactions and Precautions

Drug Interactions

Promethazine can affect various laboratory tests, including pregnancy tests and glucose tolerance tests. It should be used cautiously in patients with cardiovascular disease or impaired liver function[1].

Precautions

Phenylephrine should be used with caution in patients with cardiovascular disease, particularly hypertension. The combination should be avoided in pregnant women unless clearly needed due to the lack of adequate studies[1].

Patient Counseling and Monitoring

Monitoring

Patients should be closely monitored for respiratory depression, especially within the first 24-72 hours of initiating therapy. Reevaluation is necessary for patients with unresponsive cough to rule out underlying pathology[4].

Patient Counseling

Patients should be advised to avoid engaging in hazardous tasks requiring mental alertness, such as driving or operating machinery, due to the sedative effects of promethazine. They should also be informed about the risks of dependency and the importance of adhering to the prescribed dosage[4].

Key Takeaways

  • Clinical Trials: Limited controlled studies, particularly in pregnant women.
  • Market Analysis: Steady demand but competitive market; brand name discontinued.
  • Projections: Stable market share with potential impact from regulatory changes.
  • Dosage and Administration: Specific dosages for different age groups; not recommended for children under 2 years.
  • Drug Interactions and Precautions: Caution needed with cardiovascular and liver conditions; affects laboratory tests.
  • Patient Counseling and Monitoring: Close monitoring for respiratory depression and adherence to dosage.

FAQs

What is Phenergan VC used for?

Phenergan VC is used to treat upper respiratory symptoms such as cough, runny nose, and sneezing.

What are the common side effects of Phenergan VC?

Common side effects include sedation, sleepiness, blurred vision, dry mouth, and dizziness.

Can Phenergan VC be used in children?

Yes, but with specific dosage guidelines. It is not recommended for children under 2 years of age.

Is Phenergan VC available under its brand name?

No, the brand name has been discontinued in the U.S., but generic versions may be available.

What precautions should be taken when using Phenergan VC?

Patients with cardiovascular disease or impaired liver function should use it cautiously. It should also be avoided in pregnant women unless clearly needed.

How should patients be monitored while taking Phenergan VC?

Patients should be closely monitored for respiratory depression, especially within the first 24-72 hours of initiating therapy.

Sources

  1. RxList: Phenergan Vc (Promethazine HCl and Phenylephrine HCl Syrup)
  2. PLOS ONE: Exploratory study on “lean” or “sizzurp” using national survey data
  3. DrugBank Online: Phenytoin: Uses, Interactions, Mechanism of Action
  4. Drugs.com: Promethazine VC with Codeine: Package Insert / Prescribing Info
  5. Drugs.com: Promethazine VC: Package Insert / Prescribing Information

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.